Breadcrumb Navigation

Melanom: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02B

Stadium/Indikation inkl. Kurzinfo

Melanom – 1st line
Stadium III oder IV
Anti-PD1 + antiTIGIT vs Anti-PD1 + antiCTLA4 vs Anti-PD1 + antiCTLA4 + Lenvatinib vs Anti-PD1

Kurztitel

Merck MK3475
Substudy 02B
(UmbrellaTrial)
NCT04305054

Offizieller Titel

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02B

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Behandelnder Fachbereich

Dermatologische Klinik